Tesla's fundamentals are under pressure, according to Wells Fargo analysts, who maintain an Underweight rating and a $125 price target for the stock. Despite a 63% surge in 2024, analysts warn of weak fundamentals and risks tied to a potential repeal of the Inflation Reduction Act (IRA), which could hurt demand and margins in 2025.
Tesla’s 2024 deliveries declined by 1% year-over-year despite price cuts exceeding 5%, signaling diminishing returns. Analysts expect this trend to worsen in 2025 due to continued competition in China, a potential repeal of IRA credits, and cannibalization from new models like the "Model 2.5." Doubts remain about whether the Model Y refresh and upcoming launches can offset these challenges.
Wells Fargo highlights concerns over Tesla’s ambitious CyberCab and Optimus projects, valued at $700 billion, contrasting this with Waymo's $45 billion valuation, supported by significant operational milestones. Any regulatory or safety issues could severely impact Tesla's credibility and valuation.
The possible repeal of the $7,500 IRA tax credit could raise Tesla’s U.S. prices by 12%, threatening demand. Tesla's automotive EBIT per car, estimated at $3,600 in Q3, shows vulnerability to price wars. Price cuts in 2024, averaging 7%, already hint at a precarious strategy.
In Europe, the impact of reduced EV incentives is evident, with Tesla’s German sales dropping 41% year-over-year. A similar trend in the U.S. or Europe could exacerbate challenges.
As pricing wars continue and competitive pressures grow, Tesla faces a pivotal year in 2025. Investors remain cautious as regulatory and market dynamics threaten Tesla's profitability and growth trajectory.


SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Instagram Outage Disrupts Thousands of U.S. Users
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 



